There are 169 resources available
59P - Evaluating anticancer drug sensitivity in ALK-rearrangement-positive non-small cell lung cancer using the CODRP index-based test
Presenter: Seung Joon Kim
Session: Cocktail and Poster Display session
Resources:
Abstract
60P - Impact of eIF6 on BRAF inhibitor resistance and translation dynamics in cutaneous melanoma
Presenter: George Kyriakopoulos
Session: Cocktail and Poster Display session
Resources:
Abstract
61P - Genes affecting the sensitivity to the copanlisib/venetoclax combination in lymphoma cells identified via genetic screen
Presenter: Sara Napoli
Session: Cocktail and Poster Display session
Resources:
Abstract
62P - Phase I/II study of pazopanib and temozolomide in patients with newly diagnosed glioblastoma multiforme: PAZOGLIO trial
Presenter: Esma Saada
Session: Cocktail and Poster Display session
Resources:
Abstract
63P - Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials
Presenter: Rafael Grochot
Session: Cocktail and Poster Display session
Resources:
Abstract
64P - LX-101, a novel, clinical stage, payload-bearing IGF-1R targeted therapy, demonstrates activity in patients with high IGF-1R tumor expression
Presenter: Arkadiusz Dudek
Session: Cocktail and Poster Display session
Resources:
Abstract
65P - Preliminary results of a phase II multicenter, open-label study of fruquintinib monotherapy as third-line treatment in advanced pancreatic cancer
Presenter: Weijian Guo
Session: Cocktail and Poster Display session
Resources:
Abstract
66P - Analysis of the safety and effectiveness of TACE combined with donafenib in the treatment of intermediate and advanced hepatocellular carcinoma
Presenter: jinlong song
Session: Cocktail and Poster Display session
Resources:
Abstract
67P - Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma
Presenter: Hasan Yildirim
Session: Cocktail and Poster Display session
Resources:
Abstract
68P - Real-world clinical and treatment-related outcomes in specific subgroups of patients with BRAF-positive metastatic melanoma treated with dabrafenib-trametinib: Turkish Oncology Group study
Presenter: Eda Caliskan Yildirim
Session: Cocktail and Poster Display session
Resources:
Abstract